Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 547Carcinoma, Non-Small-Cell Lung 506Prostatic Neoplasms 332Colorectal Neoplasms 270Multiple Myeloma 266Neoplasms 260Leukemia, Myeloid, Acute 221Squamous Cell Carcinoma of Head and Neck 213Lung Neoplasms 206Neoplasm Metastasis 203Carcinoma, Hepatocellular 196Melanoma 172Triple Negative Breast Neoplasms 171Pancreatic Neoplasms 170Recurrence 152Ovarian Neoplasms 149Lymphoma 139Brain Neoplasms 132Glioblastoma 131Sarcoma 130Carcinoma, Renal Cell 126Leukemia, Lymphocytic, Chronic, B-Cell 124Head and Neck Neoplasms 124Stomach Neoplasms 122Lymphoma, Large B-Cell, Diffuse 122Rectal Neoplasms 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Myelodysplastic Syndromes 102Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

pembrolizumab 1Tadalafil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pyridoxine-dependent epilepsy × 1 year × Clear all
NCT03993353 2026-02-12

Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

University of California, San Diego

Phase 2 Completed
7 enrolled 14 charts
GastrointestinalHead & Neck

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡